Shilpa Medicare

Which are the latest news on Shilpa Medicare?

Why is Shilpa Medicare Ltd falling/rising?

As of 05-Sep, Shilpa Medicare Ltd's stock is at 964.95, having risen 200.42% year-to-date, significantly outperforming the Sensex. The stock has shown strong recent performance, reaching a 52-week high and demonstrating consistent growth in operating profit and investor confidence.

As of 05-Sep, Shilpa Medicare Ltd's stock price is rising, currently at 964.95, with a change of 9.1 (0.95%). The stock has shown strong performance, with a notable increase of 6.71% over the past week and an impressive 48.82% rise over the last month. Year-to-date, the stock has surged by 200.42%, significantly outperforming the Sensex, which has declined by 10.21% during the same period.<BR><BR>Today, the stock reached a new 52-week high of Rs. 974.9, indicating strong upward momentum. It has outperformed its sector by 0.88% today and has been on a consecutive gain streak for the last three days, accumulating a total return of 7.96% in this timeframe. Additionally, Shilpa Medicare is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is often seen as a bullish indicator.<BR><BR>The company's financial health supports this rise, with a consistent growth in operating profit at an annual rate of 31.89% and outstanding results reported for the last 12 consecutive quarters. The return on capital employed (ROCE) is at its highest at 10.52%, and net sales for the last quarter reached Rs. 465.78 crore, further bolstering investor confidence.<BR><BR>Despite some risks, such as a high debt-to-EBITDA ratio and lower profitability per unit of shareholders' funds, the overall positive performance metrics and consistent returns over the past three years contribute to the stock's upward trajectory.

Who are in the management team of Shilpa Medicare?

The management team of Shilpa Medicare includes Omprakash Inani (Chairman), Vishnukant Bhutada (Managing Director), Sharath Reddy Kalakota (Whole-time Director), and several Independent Directors: Arvind Vasudeva, Hetal Gandhi, Kamal K Sharma, and Anita Bandyopadhyay, along with Ritu Tiwary as Company Secretary. They are responsible for the company's strategic direction and regulatory compliance.

The management team of Shilpa Medicare includes the following individuals:<BR><BR>1. **Omprakash Inani** - Chairman (Non-Executive)<BR>2. **Vishnukant Bhutada** - Managing Director<BR>3. **Sharath Reddy Kalakota** - Whole-time Director<BR>4. **Arvind Vasudeva** - Independent Director<BR>5. **Hetal Gandhi** - Independent Director<BR>6. **Kamal K Sharma** - Independent Director<BR>7. **Anita Bandyopadhyay** - Independent Director<BR>8. **Ritu Tiwary** - Company Secretary & Compliance Officer<BR><BR>This team plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulations.

What does Shilpa Medicare do?

Shilpa Medicare Ltd manufactures Active Pharmaceutical Ingredients (API) and formulations, operating in the Pharmaceuticals & Biotechnology sector. As of June 2026, it reported net sales of 466 Cr and a net profit of 101 Cr, with a market cap of INR 17,319 Cr.

Overview:<BR>Shilpa Medicare Ltd is engaged in the manufacturing of Active Pharmaceutical Ingredients (API), formulations, and development services within the Pharmaceuticals & Biotechnology industry, categorized as a Small Cap company.<BR><BR>History:<BR>Shilpa Medicare Ltd was incorporated as a Private Company in 1987 and transitioned to a Public Company in 1993, changing its name to Shilpa Medicare Limited in 2003. The most recent quarterly results report net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 466 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 101 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 17,319 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 65.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.06%<BR>- Debt Equity: 0.24<BR>- Return on Equity: 8.89%<BR>- Price to Book: 6.82<BR><BR>Contact Details:<BR>Address: #12-6-214/A1, Hyderabad Road Raichur Karnataka : 584135<BR>Tel: 91-8532-238704<BR>Email: info@vbshilpa.com<BR>Website: http://www.vbshilpa.com

Who are the peers of the Shilpa Medicare?

Shilpa Medicare's peers include Pfizer, Granules India, Caplin Point Lab, ERIS Lifescience, Astrazeneca, and others. Shilpa Medicare has average management risk, good growth, and a 1-year return of 124.50%, outperforming its peers.

Peers: The peers of Shilpa Medicare are Pfizer, Granules India, Caplin Point Lab, ERIS Lifescience, Astrazeneca Phar, OneSource Speci., Alivus Life, Cohance Life, Alembic Pharma, and Concord Biotech.<BR><BR>Quality Snapshot: Excellent management risk is observed at Pfizer, Astrazeneca Phar, Granules India, Caplin Point Lab, Alivus Life, and Alembic Pharma, while Good management risk is found at ERIS Lifescience and Cohance Life. Average management risk is noted for Shilpa Medicare, while Below Average management risk is present at OneSource Speci. In terms of Growth, Excellent growth is seen at OneSource Speci., while Good growth is attributed to Shilpa Medicare, and the rest have Below Average growth. For Capital Structure, Excellent capital structure is noted at Pfizer, Granules India, Caplin Point Lab, Alivus Life, and Alembic Pharma, while Good capital structure is found at ERIS Lifescience, Average at Cohance Life, and Below Average at Shilpa Medicare.<BR><BR>Return Snapshot: Granules India has the highest 1-year return at 68.32%, while ERIS Lifescience has the lowest at -27.88%. Shilpa Medicare's 1-year return of 124.50% is significantly higher than all peers. Additionally, ERIS Lifescience, OneSource Speci., and Cohance Life have negative six-month returns.

How big is Shilpa Medicare?

As of 31st August, Shilpa Medicare Ltd has a market capitalization of 17,319.00 Cr, with recent net sales of 1,683.02 Cr and a net profit of 297.32 Cr. The company reported shareholder's funds of 2,591.20 Cr and total assets of 3,688.72 Cr as of March 2026.

As of 31st August, Shilpa Medicare Ltd has a market capitalization of 17,319.00 Cr, classifying it as a Small Cap company.<BR><BR>In the latest four quarters, Shilpa Medicare reported Net Sales of 1,683.02 Cr and a Net Profit of 297.32 Cr.<BR><BR>For the reporting period of March 2026, the company had Shareholder's Funds amounting to 2,591.20 Cr and Total Assets of 3,688.72 Cr.

Should I buy, sell or hold Shilpa Medicare Ltd?

Are Shilpa Medicare Ltd latest results good or bad?

Shilpa Medicare Ltd's latest Q1 FY27 results are positive, with a net profit of ₹100.88 crore, up 115.14% year-on-year, and revenue of ₹465.78 crore, a 44.90% increase. Despite a slight decline from the previous quarter, the company shows strong growth and operational efficiency.

Shilpa Medicare Ltd's latest results for Q1 FY27 can be considered quite positive overall. The company reported a consolidated net profit of ₹100.88 crore, which reflects a remarkable year-on-year growth of 115.14%. This indicates a strong recovery and operational performance compared to the same quarter last year.<BR><BR>In terms of revenue, Shilpa Medicare achieved ₹465.78 crore, marking a significant year-on-year increase of 44.90%. This growth is particularly impressive given the challenging environment in the pharmaceutical sector. The operating margin, excluding other income, also improved to 29.26%, up from 28.51% in the same quarter last year, demonstrating effective cost management and operational efficiency.<BR><BR>While there was a slight decline of 6.41% in net profit compared to the previous quarter, the overall trajectory shows strong demand and a solid performance across its product portfolio, especially in active pharmaceutical ingredients (APIs) and formulations. The company's ability to maintain a high operating profit to interest coverage ratio of 11.26 times further underscores its financial stability.<BR><BR>In summary, despite some quarterly fluctuations, Shilpa Medicare's latest results highlight strong growth, improved margins, and operational excellence, positioning the company favorably in the market.

When is the next results date for Shilpa Medicare Ltd?

The next results date for Shilpa Medicare Ltd is 22 May 2026.

The next results date for Shilpa Medicare Ltd is scheduled for 22 May 2026.

Is Shilpa Medicare overvalued or undervalued?

As of December 2, 2025, Shilpa Medicare's stock is considered attractive due to its undervaluation, highlighted by a PE ratio of 40.69 and a PEG ratio of 0.21, despite recent underperformance against the Sensex.

As of 2 December 2025, Shilpa Medicare's valuation grade has moved from fair to attractive, indicating a more favorable assessment of its stock. The company appears to be undervalued, especially when considering its key ratios: a PE ratio of 40.69, an EV to EBITDA of 20.27, and a PEG ratio of 0.21, which suggests strong growth potential relative to its price. <BR><BR>In comparison to its peers, Shilpa Medicare's valuation stands out; for instance, Sun Pharma has a PE ratio of 37.36 and an EV to EBITDA of 24.69, while Cipla shows a PE of 22.57 and an EV to EBITDA of 15.96, both of which are lower than Shilpa's ratios. Despite recent underperformance against the Sensex, with a year-to-date return of -16.11% compared to the Sensex's 8.96%, the attractive valuation suggests that Shilpa Medicare may present a compelling investment opportunity moving forward.

Is Shilpa Medicare technically bullish or bearish?

As of November 18, 2025, Shilpa Medicare's technical trend has shifted to bearish, indicated by a bearish MACD, Bollinger Bands, and moving averages, despite a mildly bullish signal from Dow Theory on the weekly chart.

As of 18 November 2025, the technical trend for Shilpa Medicare has changed from mildly bearish to bearish. The current technical stance is bearish with moderate strength. Key indicators driving this stance include a bearish MACD on the weekly chart, bearish Bollinger Bands, and bearish moving averages on the daily timeframe. The KST is also bearish on the weekly chart, while the Dow Theory shows a mildly bullish signal on the weekly but is mildly bearish on the monthly. Overall, the combination of these indicators suggests a prevailing bearish sentiment in the market.

How has been the historical performance of Shilpa Medicare?

Shilpa Medicare has shown significant growth in net sales, increasing from 1,050.11 Cr in March 2023 to 1,286.41 Cr in March 2025, with improved operating profit and profitability metrics. The company's total assets and shareholder's funds have also risen, indicating a stronger financial position despite a slight decline in cash flow from operating activities.

Answer:<BR>The historical performance of Shilpa Medicare shows a significant increase in net sales, reaching 1,286.41 Cr in March 2025, up from 1,151.60 Cr in March 2024 and 1,050.11 Cr in March 2023. The total operating income mirrored this growth, with a rise to 1,286.41 Cr in March 2025. However, total expenditure also increased to 969.51 Cr in March 2025, compared to 907.11 Cr in March 2024. Operating profit (PBDIT) saw a substantial rise to 340.20 Cr in March 2025 from 252.66 Cr in March 2024, indicating improved operational efficiency. Profit before tax improved to 123.60 Cr in March 2025, up from 59.11 Cr in March 2024, while profit after tax also rose to 79.57 Cr from 36.74 Cr. The earnings per share increased to 4.0 in March 2025, compared to 3.67 in March 2024. <BR><BR>On the balance sheet side, total assets grew to 3,297.74 Cr in March 2025 from 3,082.98 Cr in March 2024, with total liabilities also increasing to 3,297.74 Cr. Shareholder's funds rose to 2,372.24 Cr in March 2025 from 1,808.69 Cr in March 2024, reflecting a stronger equity position. Cash flow from operating activities was 132.00 Cr in March 2025, slightly down from 136.00 Cr in March 2024, while cash flow from investing activities showed a negative trend at -198.00 Cr. The net cash outflow was -3.00 Cr in March 2025, indicating a slight decrease in cash reserves, which stood at 28.00 Cr at the end of March 2025.<BR><BR>Breakdown:<BR>Shilpa Medicare's financial performance over the years has demonstrated a consistent upward trend in net sales, which increased from 733.39 Cr in March 2019 to 1,286.41 Cr in March 2025. This growth in revenue has been accompanied by fluctuations in operating profit, which peaked at 340.20 Cr in March 2025, showcasing improved operational efficiency despite rising expenditures. The profit before tax also reflected a positive trajectory, moving from a loss of -34.47 Cr in March 2023 to a profit of 123.60 Cr in March 2025. The company's earnings per share have rebounded from a negative figure in March 2023 to 4.0 in March 2025, indicating a recovery in profitability. On the balance sheet, total assets and shareholder's funds have both increased significantly, highlighting a strengthening financial position, while cash flow from operating activities remained stable despite a slight decline. Overall, Shilpa Medicare's financial metrics indicate a robust recovery and growth trajectory in recent years.

What is the bonus history of Shilpa Medicare?

Shilpa Medicare's most recent bonus issue was a 1:1 bonus announced on October 3, 2025. Previously, the company issued a 1:2 bonus on July 16, 2013.

Shilpa Medicare has a notable bonus history. The most recent bonus issue was a 1:1 bonus announced with an ex-date of October 3, 2025. Prior to that, the company issued a 1:2 bonus on July 16, 2013, with a record date of July 18, 2013. This reflects the company's commitment to rewarding its shareholders through bonus shares over the years.

Who are the top shareholders of the Shilpa Medicare?

The top shareholders of Shilpa Medicare include promoter Vishnukant Chaturbhuj Bhutada with 6.51%, mutual funds with 4.05%, foreign institutional investors (FIIs) at 10.97%, and individual investors holding 24.43%. The highest public shareholder is Pivotal Enterprises Private Limited with 2.25%.

The top shareholders of Shilpa Medicare include the promoters, who are the majority shareholders. The promoter with the highest holding is Vishnukant Chaturbhuj Bhutada, owning 6.51% of the company. Additionally, mutual funds hold 4.05% through 8 schemes, while foreign institutional investors (FIIs) collectively own 10.97% through 99 FIIs. The highest public shareholder is Pivotal Enterprises Private Limited, which holds 2.25%. Individual investors account for 24.43% of the holdings.

Has Shilpa Medicare declared dividend?

Yes, Shilpa Medicare Ltd has declared a 110% dividend, amounting to ₹1.1 per share, with an ex-date of September 19, 2022. Despite this, the dividend yield is 0%, as total returns have primarily come from significant price appreciation over various periods.

Shilpa Medicare Ltd has declared a 110% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 110%<BR>- Amount per share: 1.1<BR>- Ex-date: 19 Sep 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 6.35%, with no dividend return, resulting in a total return of 6.35%.<BR><BR>Over the past year, the price return was 72.64%, and there was no dividend return, leading to a total return of 72.64%.<BR><BR>In the 2-year period, the price return was 296.75%, with no dividend return, resulting in a total return of 296.75%.<BR><BR>For the 3-year period, the price return was 115.56%, with a dividend return of 0.26%, culminating in a total return of 115.82%.<BR><BR>In the 4-year period, the price return was 62.17%, with a dividend return of 0.39%, resulting in a total return of 62.56%.<BR><BR>Over the last 5 years, the price return was 95.73%, with a dividend return of 0.47%, leading to a total return of 96.2%.<BR><BR>Overall, Shilpa Medicare has declared a significant dividend, but the dividend yield remains at 0%. The total returns over various periods indicate strong price appreciation, particularly over longer time frames, despite the minimal contribution from dividends.